Peripheral T Cell Lymphoma Therapeutics
1. Beleodaq patent expiration
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6888027 | ACROTECH BIOPHARMA | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835501 | ACROTECH BIOPHARMA | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
| Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Dosage: POWDER
How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage
BELEODAQ family patents
2. Folotyn patent expiration
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6028071 | ACROTECH BIOPHARMA | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(3 years ago) | |
| US8299078 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(7 months ago) | |
| US7622470 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2014 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2016 |
Drugs and Companies using PRALATREXATE ingredient
NCE-1 date: 24 September, 2013
Market Authorisation Date: 24 September, 2009
Dosage: SOLUTION
How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage
FOLOTYN family patents
3. Istodax patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(12 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Dosage: POWDER
How can I launch a generic of ISTODAX before it's drug patent expiration?
More Information on Dosage
ISTODAX family patents